Microdosing psilocybin for chronic pain: a case series
Matthew Lyes, Joel Castellanos, Timothy Furnish, Kevin H. Yang
Pain September 5, 2022 DOI: 10.1097/j.pain.0000000000002778 via OpenAlex
Summary
AI-generated from the abstractThree individuals with chronic neuropathic pain, unresponsive to standard treatments and impairing quality of life, self-administered low doses of psilocybin. Despite differences in pain origin and preparation potency, all three achieved substantial pain relief without experiencing a psychedelic state or significant side effects. The analgesic effect was enhanced when combined with functional exercise, and in one case, repeated dosing appeared to increase relief, hinting at a possible long-term plasticity-mediated effect. The patients also reduced their reliance on conventional pain medications. These observations suggest psilocybin's therapeutic potential for chronic pain deserves further study.
Study at a glance
| Characteristics | Case series Case report Peer reviewed |
|---|---|
| Sample size | 3 |
| Population | Individuals with chronic neuropathic pain |
| Intervention | Psilocybin |
| Dose | low-dose |
| Topics | Psilocybin |
| Keywords | Series stratigraphy Chronic pain Medicine |
| Citations | 55 |
| Key finding | Low-dose psilocybin, self-administered, provided robust pain relief without psychedelic effects in three patients with chronic neuropathic pain. |
Abstract
Abstract Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end of life anxiety, and addiction when administered in hallucinogenic doses and coupled with psychotherapy. Although it has been suggested that similar high-dose protocols may help chronic pain conditions, there are few published clinical trials of psychedelics for pain. The use of these agents in subpsychedelic doses for chronic pain management has received even less attention. This case series details the experiences of 3 individuals who have used low-dose psilocybin to manage chronic neuropathic pain. Although the nature and etiology of each patient's pain vary, they share a common experience, including inefficacy of current therapeutics and decreased quality of life. Through self-administration of psilocybin, these patients have achieved robust pain relief with decreased reliance on traditional analgesic medications. Despite varying preparations and uncertain potencies, the analgesic effects for all 3 patients occurred at doses without a psychedelic experience and with minimal cognitive or somatic adverse effects. Furthermore, the efficacy of pain relief and, in some cases, the duration of the effect were magnified when coupled with functional exercise. In addition, in 1 case, repeated dosing seemed to produce increased relief, suggesting a possible long-term plasticity-mediated effect. These commonalities highlight psilocybin's therapeutic potential in the treatment of chronic pain that warrants further investigation.